Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242-1009, USA.
J Clin Microbiol. 2010 May;48(5):1592-9. doi: 10.1128/JCM.02445-09. Epub 2010 Mar 24.
The antifungal broth microdilution (BMD) method of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and the Etest agar diffusion method were compared with the Clinical and Laboratory Standards Institute (CLSI) BMD method M27-A3 for anidulafungin, caspofungin, and micafungin susceptibility testing of 133 clinical isolates of Candida species. The isolates were characterized for the presence or absence of fks1 and/or fks2 gene mutations and included 34 isolates of C. glabrata (4 mutant strains), 32 of C. albicans (1 mutant strain), 25 of C. parapsilosis, 19 of C. guilliermondii, 12 of C. tropicalis (2 mutant strains), and 11 of C. krusei. Excellent essential agreement (EA; within 2 dilutions) between the CLSI and EUCAST and CLSI and Etest MIC results was observed. The overall EA between the EUCAST and CLSI results ranged from 89.5% (caspofungin) to 99.2% (micafungin), whereas the EA between the Etest and CLSI results ranged from 90.2% (caspofungin) to 93.2% (anidulafungin). The categorical agreement (CA) between methods for each antifungal agent was assessed using previously determined epidemiological cutoff values (ECVs). Excellent CA (>90%) was observed for all comparisons between the EUCAST and CLSI results with the exceptions of C. glabrata and caspofungin (85.3%) and C. krusei and caspofungin (54.5%). The CA between the Etest and CLSI results was also excellent for all comparisons, with the exception of C. krusei and caspofungin (81.8%). All three methods were able to differentiate wild-type (WT) strains from those with fks mutations. With anidulafungin as the test reagent, the CLSI method identified 5 of 7 mutant strains, whereas the EUCAST method and the Etest identified 6 of 7 mutant strains. With either caspofungin or micafungin as the test reagent, the CLSI method identified all 7 mutant strains and the EUCAST method identified 6 of 7 mutant strains. The Etest identified all 7 mutant strains using caspofungin as the reagent. All three test methods showed a high level of agreement and of ability to distinguish fks mutant strains of Candida species from WT strains using each of the echinocandins.
本文比较了欧洲抗菌药物敏感性试验委员会(EUCAST)的抗真菌肉汤微量稀释(BMD)法和 Etest 琼脂扩散法与临床和实验室标准研究所(CLSI)BMD 方法 M27-A3 对 133 株临床分离念珠菌属物种对安尼度芬净、卡泊芬净和米卡芬净的药敏性。这些分离株的 fks1 和/或 fks2 基因突变情况进行了特征描述,包括 34 株光滑念珠菌(4 株突变株)、32 株白念珠菌(1 株突变株)、25 株近平滑念珠菌、19 株季也蒙念珠菌、12 株热带念珠菌(2 株突变株)和 11 株克柔念珠菌。CLSI 和 EUCAST 与 CLSI 和 Etest MIC 结果之间存在极好的基本一致(EA;相差 2 个稀释度)。EUCAST 和 CLSI 结果之间的总体 EA 范围为 89.5%(卡泊芬净)至 99.2%(米卡芬净),而 Etest 和 CLSI 结果之间的 EA 范围为 90.2%(卡泊芬净)至 93.2%(安尼度芬净)。使用先前确定的流行病学截断值(ECV)评估了每种抗真菌药物之间方法的分类一致率(CA)。除了光滑念珠菌和卡泊芬净(85.3%)以及克柔念珠菌和卡泊芬净(54.5%)之外,EUCAST 和 CLSI 结果之间的所有比较均观察到极好的 CA(>90%)。Etest 和 CLSI 结果之间的 CA 也非常好,除了克柔念珠菌和卡泊芬净(81.8%)。所有三种方法都能够区分野生型(WT)株和 fks 突变株。以安尼度芬净作为检测试剂时,CLSI 方法鉴定出 7 株突变株中的 5 株,而 EUCAST 方法和 Etest 鉴定出 7 株突变株中的 6 株。使用卡泊芬净或米卡芬净作为检测试剂时,CLSI 方法鉴定出所有 7 株突变株,EUCAST 方法鉴定出 7 株突变株中的 6 株。Etest 使用卡泊芬净作为试剂鉴定出所有 7 株突变株。所有三种检测方法均显示出较高的一致性和能力,能够使用每种棘白菌素区分棘白菌素敏感念珠菌属物种的 fks 突变株和 WT 株。